Efficacy and safety of Zolbetuximab plus chemotherapy for advanced CLDN18.2- positive gastric or gastro-oesophageal adenocarcinoma: A meta-analysis of randomized clinical trials

The benefit of adding Zolbetuximab to the treatment in patients with Claudin-18 isoform 2 (CLDN18.2)- positive, human epidermal growth factor receptor 2-negative, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GC/GEJ) is not yet fully elucidated.